Anebulo Pharmaceuticals (NASDAQ:ANEB) Shares Down 3.8% – Should You Sell?

Posted by Brian Himes on May 23rd, 2026

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Free Report) was down 3.8% during mid-day trading on Thursday . The company traded as low as $0.46 and last traded at $0.4762. Approximately 1,216 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 50,859 shares. The stock had previously closed at $0.4950.

Anebulo Pharmaceuticals Stock Down 3.4%

The company has a market cap of $18.76 million, a PE ratio of -2.42 and a beta of -1.93. The business has a 50-day simple moving average of $0.63 and a 200-day simple moving average of $1.12.

Institutional Trading of Anebulo Pharmaceuticals

A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. bought a new position in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned approximately 0.12% of Anebulo Pharmaceuticals at the end of the most recent quarter. 28.40% of the stock is currently owned by hedge funds and other institutional investors.

About Anebulo Pharmaceuticals

(Get Free Report)

Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.

The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S.